Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch
Can Gamida Succeed On Its Own?
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
You may also be interested in...
Acacia launched two hospital drugs – Barhemsys and Byfavo – in the US during COVID but failed to overcome the physical access limitations caused by the pandemic. Eagle of the US thinks it can tap into a potentially lucrative market and is buying the beleaguered biotech.
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.